Soleno Therapeutics 주식 (NASDAQ: SLNO)

에 대한 최신 뉴스 Soleno Therapeutics (NASDAQ:SLNO) 주식

Soleno Therapeutics

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Biotech

Equities

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Market Summary

Mid Cap

Health Care

Small Cap

Tech

$BTC

AVGO

CVNA

MSTR

NVDA

SLNO

TSLA

VERA

엔비디아(NASDAQ:NVDA)는 지난 1년간 수익률 순위에서 나스닥 100 지수 1위를 차지하며 눈에 띄는 기술 주식이었다.
이 칩 제조업의 거인은 인공지능(AI) 개발을 위한 칩에 대한 급증하는 수요로, 지난 2023년 5월 말 이후 무려 186%나 급등했다.

엔비디아는 1년 전 대비 186% 상승했지만, 다음의 7개 주식은 이보다 두 배 이상의 수익 기록

Soleno Therapeutics Inc

<p><strong>American Express Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is set to report its fourth-quarter financial results on Friday before the opening bell. Here's what investors will be watching for when the financial <a href="https://www.benzinga.com/25/01/43086592/financial-crime-weekly-american-express-pays-108-million-to-settle-deceptive-marketing-charges-vanguard-group-pays-106-million-for-violations">services giant reports.&nbsp;</a></p>
<p><strong>What To Watch: </strong>Analysts expect American Express to post earnings of $3.04 per share and quarterly revenue of $17.16 billion, according to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. The company has beat earnings expectations in each of the first three quarters of 2024.&nbsp;</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43136971/will-soundhound-ai-stock-get-a-boost-from-project-stargate"><strong>Will SoundHound AI Stock Get A Boost From Project Stargate?&nbsp;</strong></a></p>
<p>Wall Street analysts and investors are likely interested in credit metrics, including net charge-offs and delinquency rates, which impact the company&#8217;s profitability and risk profile. They also provide insight into the strength of the consumer. </p>
<p>Investors will also be looking for growth in net interest income which has been a key driver of revenue increases for the company. Net interest income was $4 billion for the third quarter, up 7.4% from $3.7 billion year-over-year.<mark class="annotation-text annotation-text-yoast" id="annotation-text-e7a78bc7-f147-43ab-8ccb-115687c75a18"></mark></p>
<p>RBC Capital&#8217;s<strong> </strong>Jon Arfstrom<strong> </strong>maintained American Express with a Buy rating. He also raised its price target from $315 to $330 heading into earnings. The analyst expects "steady fundamental results" with higher spending volumes and loan growth driven by holiday season tailwinds, as reported by TipRanks.    </p>
<p>American Express shares have gained more than 70% over the past year. They&#8217;re trading at 52-week highs heading into its fourth-quarter report Friday morning. </p>
<p><strong>Price Action: </strong>According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, American Express shares are trading at 52-week highs, up 0.68% at $324.46 at the time of publication Thursday. </p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43130930/trump-looking-at-10-tariff-on-china-starting-feb-1"><strong>Trump &#8216;Looking At&#8217; 10% Tariff On China Starting Feb. 1&nbsp;</strong></a></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Earnings

News

Previews

American Express Reports Q4 Results Friday: Net Charge-Offs, Delinquency Rates Among Items To Watch

JPMorgan Says During 2024 It Continued To Serve Clients And Customers Against Dynamic Global Macro Backdrop Characterized By Ongoing Geopolitical Tensions And Economic Uncertainty

<p>SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.56 by 10.71 percent. This is a 30.56 percent decrease over earnings of $0.72 per share from the same period last year.  The company reported quarterly sales of $362.00 million which missed the analyst consensus estimate of $373.96 million by 3.20 percent.  This is a 6.22 percent decrease over sales of $386.00 million the same period last year.</p>


Earnings Misses

SLM Q4 EPS $0.50 Misses $0.56 Estimate, Sales $362.00M Miss $373.96M Estimate

<p>Glacier Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBCI#NYSE">GBCI</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.52 by 3.85 percent. This is a 10.2 percent increase over earnings of $0.49 per share from the same period last year.</p>


Earnings Beats

GBCI

Glacier Bancorp Q4 2024 GAAP EPS $0.54 Beats $0.52 Estimate

CUBI

Customers Bancorp Q4 2024 Core EPS $1.36 Beats $1.21 Estimate

Contracts

Granite Has Been Awarded An ~$88 Million Contract By The California Department Of Transportation

WIIM

Dyne Therapeutics shares are trading higher after the company announced it received FDA Fast Track designation for DYNE-101 to treat myotonic dystrophy type 1.

ACNB

ACNB Q4 2024 GAAP EPS $0.77 Misses $0.84 Estimate

<p><strong>CSX</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) just disclosed its Q4 earnings on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>CSX missed estimated earnings by 0.0%, reporting an EPS of $0.42 versus an estimate of $0.42.</p>
<p>Revenue was down $140.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.02, leading to a 7.000000000000001% drop share price change the next day.</p>
<p>Here's a look at CSX's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.48</td>
<td>0.48</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.46</td>
<td>0.49</td>
<td>0.46</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.67B</td>
<td>3.70B</td>
<td>3.66B</td>
<td>3.63B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.62B</td>
<td>3.70B</td>
<td>3.68B</td>
<td>3.68B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for CSX <a href="https://www.benzinga.com/quote/CSX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CSX Earnings Review: Q4 Summary

<p><strong>Columbia Banking System</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:02 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Columbia Banking System beat estimated earnings by 9.0%, reporting an EPS of $0.71 versus an estimate of $0.65.</p>
<p>Revenue was down $32.04 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company beat on EPS by $0.07 in the previous quarter, leading to a 1.0% drop share price change the next day.</p>
<p>Here's a look at Columbia Banking System's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.62</td>
<td>0.57</td>
<td>0.53</td>
<td>0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>0.67</td>
<td>0.65</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>481.03M</td>
<td>475.95M</td>
<td>480.36M</td>
<td>526.68M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>496.38M</td>
<td>472.15M</td>
<td>473.72M</td>
<td>519.16M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Columbia Banking System <a href="https://www.benzinga.com/quote/COLB/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


COLB

Columbia Banking System: Q4 Earnings Insights

<p>Vale Base Metals has launched a strategic review to explore and evaluate a range of alternatives, including the potential sale, for its mining and exploration assets in Thompson, Manitoba, the Canadian-based subsidiary of Vale SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>) announced today.</p>
<p>The Thompson review is part of a process to optimize Vale Base Metals' global mining portfolio to enable copper growth in the Carajas region and ensure the competitiveness of its vertically integrated nickel portfolio to create long-term value for its shareholders and stakeholders.</p>
<p>Vale Base Metals has engaged an external advisor to lead the Thompson review, which is expected to conclude in 2H 2025.</p>
<p>The Thompson Nickel Belt is a proven nickel deposit with significant resource upside and the operations have been producing nickel since 1956. The assets include two operating underground mines, an adjacent mill and significant exploration opportunities on the 135-km long Thompson Nickel Belt. Thompson produced 10.5 thousand metric tonnes of Vale Base Metals' finished nickel for the 12-month period ending Q3 2024.</p>


VALE

Vale Base Metals Initiates Strategic Review for Potential Sale of Thompson Mining Assets in Manitoba; Expected Conclusion in H2 2025, Involving Two Mines and Exploration Sites; Produced 10.5K Metric Tonnes of Nickel by Q3 2024

<p>The earnings results for <strong>Intuitive Surgical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) for Q4 were made public on Thursday, January 23, 2025 at 04:04 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Intuitive Surgical beat estimated earnings by 23.0%, reporting an EPS of $2.21 versus an estimate of $1.79.</p>
<p>Revenue was up $485.70 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.21 in the previous quarter, leading to a 10.0% increase share price change the next day.</p>
<p>Here's a look at Intuitive Surgical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.63</td>
<td>1.54</td>
<td>1.41</td>
<td>1.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.84</td>
<td>1.78</td>
<td>1.50</td>
<td>1.60</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.00B</td>
<td>1.97B</td>
<td>1.87B</td>
<td>1.87B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.04B</td>
<td>2.01B</td>
<td>1.89B</td>
<td>1.93B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Intuitive Surgical <a href="https://www.benzinga.com/quote/ISRG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ISRG

Earnings Breakdown: Intuitive Surgical Q4

<p><strong>Texas Instruments</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) just disclosed its Q4 earnings on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Texas Instruments beat estimated earnings by 8.0%, reporting an EPS of $1.3 versus an estimate of $1.2.</p>
<p>Revenue was down $70.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.09 in the last quarter, resulting in a 4.0% increase share price change the following day.</p>
<p>Here's a look at Texas Instruments's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.38</td>
<td>1.17</td>
<td>1.07</td>
<td>1.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.47</td>
<td>1.22</td>
<td>1.20</td>
<td>1.49</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>4.12B</td>
<td>3.82B</td>
<td>3.61B</td>
<td>4.12B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>4.15B</td>
<td>3.82B</td>
<td>3.66B</td>
<td>4.08B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Texas Instruments management provided guidance for Q1 2025, expecting earnings between $0.94 and $1.16 per share.</p>
<p>To track all earnings releases for Texas Instruments <a href="https://www.benzinga.com/quote/TXN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Texas Instruments Earnings Report: Q4 Overview

<p><strong>Metropolitan Bank Holding</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCB#NYSE">MCB</a>) reported its Q4 earnings results on Thursday, January 23, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Metropolitan Bank Holding beat estimated earnings by 26.0%, reporting an EPS of $1.88 versus an estimate of $1.49.</p>
<p>Revenue was up $7.45 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.31 in the previous quarter, leading to a 7.000000000000001% drop share price change the next day.</p>
<p>Here's a look at Metropolitan Bank Holding's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.55</td>
<td>1.57</td>
<td>1.34</td>
<td>1.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.86</td>
<td>1.50</td>
<td>1.46</td>
<td>1.28</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>66.73M</td>
<td>67.89M</td>
<td>64.56M</td>
<td>61.68M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>71.52M</td>
<td>67.68M</td>
<td>66.71M</td>
<td>63.55M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Metropolitan Bank Holding <a href="https://www.benzinga.com/quote/MCB/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Metropolitan Bank Holding Q4

<p><strong>Business First Bancshares</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFST#NASDAQ">BFST</a>) announced its Q4 earnings on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Business First Bancshares beat estimated earnings by 35.0%, reporting an EPS of $0.66 versus an estimate of $0.49.</p>
<p>Revenue was up $17.41 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.11 in the last quarter, resulting in a 4.0% increase share price change the following day.</p>
<p>Here's a look at Business First Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.57</td>
<td>0.51</td>
<td>0.57</td>
<td>0.60</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.68</td>
<td>0.64</td>
<td>0.50</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>65.32M</td>
<td>62.96M</td>
<td>62.22M</td>
<td>62.47M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>66.90M</td>
<td>66.19M</td>
<td>60.92M</td>
<td>60.17M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Business First Bancshares <a href="https://www.benzinga.com/quote/BFST/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BFST

Earnings Breakdown: Business First Bancshares Q4

<p>The Q4 earnings report for <strong>Covenant Logistics Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVLG#NYSE">CVLG</a>) was released on Thursday, January 23, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Covenant Logistics Gr missed estimated earnings by 0.0%, reporting an EPS of $0.49 versus an estimate of $0.49.</p>
<p>Revenue was up $3.35 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 0.0% increase in the share price the next day.</p>
<p>Here's a look at Covenant Logistics Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.55</td>
<td>0.49</td>
<td>0.39</td>
<td>0.52</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.55</td>
<td>0.52</td>
<td>0.42</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>299.81M</td>
<td>292.63M</td>
<td>273.30M</td>
<td>281.75M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>258.60M</td>
<td>287.50M</td>
<td>278.76M</td>
<td>273.99M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Covenant Logistics Gr <a href="https://www.benzinga.com/quote/CVLG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CVLG

Covenant Logistics Gr Earnings Analysis: Q4 Recap

<p><strong>MidWestOne Financial Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOFG#NASDAQ">MOFG</a>) reported its Q4 earnings results on Thursday, January 23, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>MidWestOne Financial Gr beat estimated earnings by 7.000000000000001%, reporting an EPS of $0.77 versus an estimate of $0.72.</p>
<p>Revenue was up $16.38 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>In the previous quarter, the company beat on EPS by $0.02, resulting in a 3.0% drop change in the share price the following day.</p>
<p>Here's a look at MidWestOne Financial Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.56</td>
<td>0.49</td>
<td>0.39</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.58</td>
<td>0.50</td>
<td>0.21</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>37.44M</td>
<td>37.53M</td>
<td>34.58M</td>
<td>34.02M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>37.52M</td>
<td>36.35M</td>
<td>34.73M</td>
<td>32.56M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for MidWestOne Financial Gr <a href="https://www.benzinga.com/quote/MOFG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MOFG

MidWestOne Financial Gr Q4 Earnings Assessment

<p>Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) has outperformed the market over the past 5 years by 70.96% on an annualized basis producing an average annual return of 84.24%. Currently, Antero Resources has a market capitalization of $12.62 billion. </p>
<p><strong>Buying $100 In AR:</strong> If an investor had bought $100 of AR stock 5 years ago, it would be worth <strong>$2,203.80</strong> today based on a price of $40.55 for AR at the time of writing.</p>
<h3>Antero Resources's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737667807_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

Here's How Much $100 Invested In Antero Resources 5 Years Ago Would Be Worth Today

<p><strong>First Western Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYFW#NASDAQ">MYFW</a>) just disclosed its Q4 earnings on Thursday, January 23, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>First Western Financial beat estimated earnings by 8.0%, reporting an EPS of $0.28 versus an estimate of $0.26.</p>
<p>Revenue was up $955 thousand from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company missed on EPS by $0.06 in the last quarter, resulting in a 7.000000000000001% drop share price change the following day.</p>
<p>Here's a look at First Western Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.28</td>
<td>0.30</td>
<td>0.22</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.22</td>
<td>0.11</td>
<td>0.26</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>24.12M</td>
<td>24.20M</td>
<td>22.97M</td>
<td>23.83M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>22.54M</td>
<td>22.75M</td>
<td>23.35M</td>
<td>22.41M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for First Western Financial <a href="https://www.benzinga.com/quote/MYFW/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MYFW

Earnings Summary: First Western Financial Q4

3D Systems shares are trading higher after the company and Daimler Buses announced a solution for remote spare part printing.

In a report released today, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report), with a price t...

Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) on November 6 and set a price target ...

Positive Outlook for Soleno Therapeutics: Buy Rating Based on Anticipated FDA Approval and Strong Cash Position

Soleno Therapeutics ( ($SLNO) ) has released its Q3 earnings. Here is a breakdown of the information Soleno Therapeutics presented to its investors...

Soleno Therapeutics Reports Q3 Progress and Financials

Soleno Therapeutics slides after FDA review extension of its Prader-Willi syndrome treatment

Soleno Therapeutics (SLNO) announced that the U.S. Food and Drug Administration, FDA, has extended the review period for the New Drug Application, ...

Soleno Therapeutics announces U.S.. FDA to ended review period for NDA

Welcome to this week's installment of "The Short Interest Report" – The Fly's weekly recap of short interest trends among some of the most widely f...

Short Report: Bears look to fade Archer Aviation ascent

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Soleno Therapeutics (SLNO – Research Report), with a pric...

Confident Buy Rating on Soleno Therapeutics Amidst Imminent FDA Approval and Strong Valuation

Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me

Soleno Therapeutics enters into $200M debt financing with Oxford Finance

Catalyst Watch: Labor pains for Amazon & Starbucks, Nasdaq call-up for MicroStrategy and Pony AI ratings

ACHR

ALMS

AMCX

AMTM

AMZN

AXON

CRVL

DNTH

DXST

GALT

GLATF

GOEV

ILMN

KELYA

LMNR

MRNA

NDSN

NMRA

NUKK

PLTR

PONY

QMCO

QRVO

QUBT

RYTM

SAVA

SBUX

SMCI

WBTN

WDAY

Press Releases

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

Management

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Financing

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Akero Therapeutics

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Geron

ImmunityBio

IDEAYA Biosciences

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Disc Medicine

Janux Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MannKind

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Baird

HC Wainwright & Co.

Oppenheimer

Stifel

Cantor Fitzgerald

<p><strong>엔비디아</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 지난 1년간 <a href="https://www.benzinga.com/quote/NVDA/news" target="_blank" rel="noopener">수익률 순위</a>에서 <strong>나스닥 100 지수</strong> 1위를 차지하며 눈에 띄는 기술 주식이었다.</p>
<p>이 칩 제조업의 거인은 인공지능(AI) 개발을 위한 칩에 대한 급증하는 수요로, 지난 2023년 5월 말 이후 무려 186%나 급등했다.</p>
<p>베테랑 월스트리트 투자자 <strong>에드 야데니</strong>(Ed Yardeni)는 최근 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39037833/magnificent-7-becomes-the-magnificent-one-wall-street-guru-hails-single-tech-stock-">매그니피센트 7</a>(Magnificent Seven)과 엔비디아의 탁월한 성능을 차별화하기 위해 &#8216;매그니피센트 1(Magnificent One)&#8217;을 만들었다.</p>
<p>엔비디아의 시장 가치 증가 규모를 설명하기 위해 불과 1년 전만 해도 엔비디아의 가치는 1조 달러로 평가되었다. 오늘날 이 회사는 2조 8천억 달러라는 엄청난 가치를 자랑하며 미국에서 세 번째로 큰 회사가 되었다.</p>
<p>엔비디아의 현재 가치는 <strong>테슬라</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), <b>일라이 릴리</b>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), <strong>브로드컴</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), <b>월마트</b>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) 및 <strong>마스터카드</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>)의 시장가치 합계와 동일하다.</p>
<p><em>자세히 보기: <a href="https://www.benzinga.com/general/education/24/05/39063462/when-will-nvidia-be-the-most-valuable-company-in-the-world">엔비디아가 세계에서 가장 가치 있는 회사가 될 때는 언제일까?</a></em></p>
<p>그러나 엔비디아의 눈부신 상승세는 지난 1년간 이 칩 제조업체의 인상적인 수익률을 두 배 이상 증가시킨 미국 주식 7개에 의해 가려졌다.</p>
<h2 class="wp-block-heading"><strong>7. 베라 테라퓨틱스</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>)- 363%</h2>
<p>베라 테라퓨틱스는 심각한 면역 질환에 대한 혁신적인 치료제 개발에 전념한 바이오제약 기업이다. 이 회사의 주식은 임상 프로그램의 진전과 약품 후보물질에 대한 낙관적인 예상으로 급등했다.</p>
<p>2023년 5월 30일 이후 363%의 급등을 기록했으며, 동일 기간 동안 엔비디아의 수익률을 두 배로 능가했다.</p>
<h2 class="wp-block-heading"><strong>6. 버티브 홀딩스</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)- <strong>413%</strong></h2>
<p>버티브 홀딩는 중요한 디지털 인프라 및 연속성 솔루션을 제공한다. 이 회사는 데이터 센터 및 IT 인프라에 대한 수요가 증가한 데에 힘입어 강력한 재무 성과를 거두고, 결과적으로 주가가 크게 상승했다.</p>
<h2 class="wp-block-heading"><strong>5. 마이크로스트레티지</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)- <strong>441%</strong></h2>
<p>마이크로스트레티지는 비즈니스 인텔리전스 기업으로, <strong>비트코인</strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)에 대한 상당한 투자로 주목받았다.</p>
<p>이 회사의 주식 수익률 비트코인 가격 변동과 밀접한 관련이 있으며, 주가는 비트코인의 상승과 함께 급등했다. 이 가장 큰 암호화폐는 지난 2023년 5월 말 이후 140%의 상승을 기록했다.</p>
<h2 class="wp-block-heading"><strong>4. 애버크롬비 &amp; 피치</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>)- <strong>503%</strong></h2>
<p>애버크롬비 &amp; 피치는 캐주얼 웨어 및 라이프스타일 제품으로 유명한 명품 패션 리테일러이다. 이 회사의 주가 강세는 강력한 전환 노력, 강력한 전자상거래 성장 및 개선된 수익성 지표로 인해 투자자의 관심을 끌었다.</p>
<h2 class="wp-block-heading"><strong>3. 카바나</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NASDAQ">CVNA</a>)- <strong>666%</strong></h2>
<p>카바나는 온라인 중고차 리테일러로, 자택 배달 및 7일 내 반품 정책을 갖춘 완전 온라인 플랫폼을 통해 차량 구매 경험을 혁신하였다.</p>
<p>이 회사는 어려웠던 시기를 겪은 지속적인 회복과 특별한 사업 모델 및 성장 가능성에 대한 투자자의 신뢰회복으로 주가가 급등했다.</p>
<h2 class="wp-block-heading"><strong>2. 솔레노 테라퓨틱스</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>)- <strong>697%</strong></h2>
<p>솔레노 테라퓨틱스는 프라더 윌리(Prader-Willi) 증후군과 같은 희귀 질병에 대한 치료제 개발에 초점을 맞춘 회사이다. 이 회사의 주식은 긍정적인 임상 시험 결과와 약품 후보물질 파이프라인에 대한 낙관적 전망으로 인해 급등했다.</p>
<h2 class="wp-block-heading"><strong>1. 머니라이언</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>)- <strong>790%</strong></h2>
<p>머니라이언는 개인 대출, 신용 빌딩 서비스 및 금융 자문 도구를 비롯한 다양한 제품을 제공하는 디지털 금융 플랫폼이다. 이 회사의 상당한 주가 급등은 핀테크 서비스의 공격적인 확장과 혁신에 의해 주도되었으며, 접근 가능한 금융 솔루션을 찾는 광범위한 고객 기반에 어필하고 있다.</p>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-361859" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-1024x500.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119-1536x750.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/29161150/image-119.png 1920w" alt="" width="1024" height="500" /></figure>
<p><em>사진: 셔터스톡</em></p>
<p><em><strong>놓치지 마세요:</strong> 미국 평균 부부의 퇴직을 위한 저축액 &#8211; 얼마나 모으셨나요? <a href="http://www.benzinga.com/money/smartasset" target="_blank" rel="noreferrer noopener">비교해보세요</a></em></p>

Comments

Soleno Therapeutics

뉴스

에 대한 최신 뉴스 Soleno Therapeutics (NASDAQ:SLNO) 주식

수요일, 5월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌